{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nerve+Sheath+Neoplasms&page=2", "query": { "condition": "Nerve Sheath Neoplasms", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nerve+Sheath+Neoplasms&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T21:51:56.185Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00727233", "title": "Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neurofibromatosis Type I", "Plexiform Neurofibroma" ], "interventions": [ { "name": "Nexavar (BAY 43-9006) (Sorafenib)", "type": "DRUG" }, { "name": "Toxicity, Pharmacokinetics", "type": "DRUG" }, { "name": "Pharmacodynamics", "type": "DRUG" }, { "name": "Radiographic Evaluation", "type": "DRUG" }, { "name": "QOL assessment, Neuropsychological", "type": "DRUG" }, { "name": "Bony Toxicity", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 9, "start_date": "2008-07-08", "completion_date": "2011-06-16", "has_results": false, "last_update_posted_date": "2019-12-12", "last_synced_at": "2026-06-26T21:51:56.185Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Bethesda, Maryland", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00727233" }, { "nct_id": "NCT01222728", "title": "Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neoplasms", "Nervous System Disease", "Vestibular Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 5, "start_date": "2010-09-22", "completion_date": "2015-06-03", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-06-26T21:51:56.185Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222728" }, { "nct_id": "NCT00837148", "title": "Sorafenib and Dacarbazine in Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma", "Synovial Sarcoma", "Leiomyosarcoma", "Malignant Peripheral Nerve Sheath Tumor" ], "interventions": [ { "name": "Sorafenib and Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2009-02", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-06-26T21:51:56.185Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00837148" }, { "nct_id": "NCT03095248", "title": "Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neurofibromatosis 2", "Vestibular Schwannoma", "Meningioma", "Ependymoma", "Glioma" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "3 Years to 45 Years" }, "enrollment_count": 10, "start_date": "2017-05-08", "completion_date": "2024-05-21", "has_results": true, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-06-26T21:51:56.185Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03095248" }, { "nct_id": "NCT01552434", "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Neoplasm", "Castleman Disease", "Digestive System Carcinoma", "Erdheim-Chester Disease", "Lip and Oral Cavity Carcinoma", "Lymphangioleiomyomatosis", "Malignant Endocrine Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Male Reproductive System Neoplasm", "Malignant Neoplasm", "Malignant Respiratory Tract Neoplasm", "Malignant Thoracic Neoplasm", "Malignant Urinary System Neoplasm", "Mesothelial Neoplasm", "Metastatic Malignant Neoplasm", "Metastatic Urothelial Carcinoma", "Neurofibromatosis Type 2", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Breast Carcinoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Digestive System Carcinoma", "Recurrent Female Reproductive System Carcinoma", "Recurrent Male Reproductive System Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Pharyngeal Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Malignant Neoplasm", "Soft Tissue Neoplasm", "Stage III Breast Cancer AJCC v7", "Stage III Pharyngeal Cancer", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Pharyngeal Cancer", "Stage IVA Pharyngeal Cancer", "Stage IVB Pharyngeal Cancer", "Stage IVC Pharyngeal Cancer", "Thyroid Gland Neoplasm" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 154, "start_date": "2012-10-16", "completion_date": "2026-05-08", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-26T21:51:56.185Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552434" }, { "nct_id": "NCT03975829", "title": "Pediatric Long-Term Follow-up and Rollover Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diffuse Astrocytoma", "Anaplastic Astrocytoma", "Astrocytoma", "Oligodendroglioma, Childhood", "Anaplastic Oligodendroglioma", "Glioblastoma", "Pilocytic Astrocytoma", "Giant Cell Astrocytoma", "Pleomorphic Xanthoastrocytoma", "Anaplastic Pleomorphic Xanthoastrocytoma", "Angiocentric Glioma", "Chordoid Glioma of Third Ventricle", "Gangliocytoma", "Ganglioglioma", "Anaplastic Ganglioglioma", "Dysplastic Gangliocytoma of Cerebrellum", "Desmoplastic Infantile Astrocytoma and Ganglioglioma", "Papillary Glioneuronal Tumor", "Rosette-forming Glioneuronal Tumor", "Central Neurocytoma", "Extraventricular Neurocytoma", "Cerebellar Liponeurocytoma", "Neurofibromatosis Type 1" ], "interventions": [ { "name": "dabrafenib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Year to 99 Years" }, "enrollment_count": 165, "start_date": "2019-11-04", "completion_date": "2026-11-05", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-06-26T21:51:56.185Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Miami, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03975829" }, { "nct_id": "NCT04897321", "title": "B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pediatric Solid Tumor", "Osteosarcoma", "Rhabdomyosarcoma", "Neuroblastoma", "Ewing Sarcoma", "Wilms Tumor", "Adrenocortical Cancer", "Desmoplastic Small Round Cell Tumor", "Germ Cell Cancer", "Rhabdoid Tumor", "Clear Cell Sarcoma", "Hepatoblastoma", "Melanoma", "Carcinoma", "Malignant Peripheral Nerve Sheath Tumors", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "MESNA", "type": "DRUG" }, { "name": "B7-H3 CAR T cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 48, "start_date": "2022-07-06", "completion_date": "2028-03-01", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-06-26T21:51:56.185Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04897321" }, { "nct_id": "NCT01410006", "title": "Neurofibromatosis Type 1 Patient Registry", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neurofibromatosis Type 1" ], "interventions": [], "intervention_types": [], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2391, "start_date": "2011-05", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2017-07-25", "last_synced_at": "2026-06-26T21:51:56.185Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01410006" }, { "nct_id": "NCT00053937", "title": "Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neurofibromatosis Type 1", "Precancerous Condition" ], "interventions": [ { "name": "pirfenidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": null, "start_date": "2002-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-06-26T21:51:56.185Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053937" }, { "nct_id": "NCT03141021", "title": "Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Malignant Peripheral Nerve Sheath Tumors" ], "interventions": [], "intervention_types": [], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1050, "start_date": "2017-04-28", "completion_date": "2053-04-30", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-06-26T21:51:56.185Z", "location_count": 9, "location_summary": "Tampa, Florida • Baltimore, Maryland • Bethesda, Maryland + 6 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03141021" } ] }